rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    UNCY
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
      Nov 16Yahoo FinanceUNCY
      Unicycive Therapeutics at Guggenheim conference: launch plan takes shape
      Nov 10Investing.comUNCY
      Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
      Nov 4BenzingaUNCY
      CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
      Nov 2MorningstarUNCY
      Unicycive Therapeutics: 95% Upside Priced Against A Wall Of Dilution And Regulatory Risk
      Oct 31Seeking AlphaUNCY
      UNCY Class Action Lawsuit - Robbins LLP Reminds Unicycive Therapeutics, Inc. Investors of the November 2, 2026 Lead Plaintiff Deadline

      Newsfile Press Release.

      Oct 26The Globe and MailUNCY
      What's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
      Oct 23MorningstarUNCY
      UNCY UPCOMING DEADLINE: SueWallSt Alerts Unicycive Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm
      Oct 22MorningstarUNCY
      Robbins LLP Reminds UNCY Investors of the Pending Lead Plaintiff Deadline in the Unicycive Therapeutics, Inc. Securities Class Action Lawsuit
      Oct 22MorningstarUNCY
      FDA accepts Unicycive resubmission for kidney drug application
      Oct 22Investing.comUNCY
      What Should Unicycive Therapeutics, Inc. Investors Know After 39.1% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline
      Oct 21MorningstarUNCY
      Why is Unicycive Therapeutics stock rallying today?
      Oct 21Investing.comUNCY
      Unicycive stock jumps as FDA accepts OLC drug resubmission
      Oct 21Investing.comUNCY
      FDA accepts Unicycive resubmission for kidney disease drug
      Oct 21Investing.comUNCY
      Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027

      Resubmission includes Chemistry, Manufacturing, and Controls (CMC) data from new drug product (DP) manufacturing vendor MOUNTAIN VIEW, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbona

      Oct 21Yahoo FinanceUNCY
      UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
      Oct 21MorningstarUNCY
      SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. Lawsuit - UNCY
      Oct 15MorningstarUNCY
      Levi & Korsinsky Reminds Unicycive Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 2, 2026 - UNCY
      Oct 14MorningstarUNCY
      Kaplan Fox Alerts Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Seek Leadership in a Securities Fraud Lawsuit by November 2, 2026

      Detailed price information for Unicycive Therapeutics Inc (UNCY-Q) from The Globe and Mail including charting and trades.

      Oct 14The Globe and MailUNCY
      Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
      Oct 13Yahoo FinanceUNCY
      Kaplan Fox & Kilsheimer LLP Alerts Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to the Lead Plaintiff Deadline on November 2, 2026

      NewMediaWire Press Release.

      Oct 12The Globe and MailUNCY
      UNCY Deadline Alert: SueWallSt Reminds Unicycive Therapeutics, Inc. (UNCY) Investors of Securities Class Action Deadline on November 2, 2026
      Oct 8MorningstarUNCY
      Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
      Oct 7MorningstarUNCY
      UNCY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
      Oct 7BarchartUNCY
      UNCY UPCOMING DEADLINE: Levi & Korsinsky Alerts Unicycive Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm
      Oct 7MorningstarUNCY
      Kaplan Fox Class Action Reminder: Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Lead Plaintiff Deadline is November 2, 2026

      Detailed price information for Unicycive Therapeutics Inc (UNCY-Q) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailUNCY
      Unicycive Therapeutics Appoints Meredith Manning to Board of Directors

      B2i Digital Press Release.

      Oct 1The Globe and MailUNCY
      UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt
      Oct 1MorningstarUNCY
      Unicycive appoints Meredith Manning to board of directors
      Oct 1Investing.comUNCY
      Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Unicycive Therapeutics (UNCY)

      Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

      Sep 30The Globe and MailUNCYVRTX
      Kaplan Fox Shareholder Alert: Deadline to Lead in the Securities Fraud Lawsuit Against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is November 2, 2026
      Sep 30BarchartUNCY
      Robbins LLP Urges UNCY Stockholders with Significant Losses to Contact the Firm for Information About the Unicycive Therapeutics, Inc. Class Action
      Sep 30MorningstarUNCY
      Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate - Unicyc

      Mountain View, California, September 29th, 2026, FinanceWireResubmission of NDA includes Chemistry, Manufacturing, and Controls (CMC) data from a new drug product manufacturing vendorThe resubmission package includes 12

      Sep 29BenzingaUNCY
      Unicycive resubmits NDA for kidney disease drug with new vendor
      Sep 29Investing.comUNCY
      Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
      Sep 29Yahoo FinanceUNCY
      UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
      Sep 29MorningstarUNCY
      Unicycive Therapeutics faces securities class action lawsuit over public statements
      Sep 28Investing.comUNCY
      Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Deadline on November 2, 2026

      Detailed price information for Unicycive Therapeutics Inc (UNCY-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailUNCY
      UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact SueWallSt
      Sep 24MorningstarUNCY
      Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
      Sep 23MorningstarUNCY
      Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 2, 2026

      NewMediaWire Press Release.

      Sep 22The Globe and MailUNCY
      Robbins LLP is Investigating Allegations that Unicycive Therapeutics, Inc. Failed to Properly Inspect its Third-Party Vendor's Manufacturing Facility to Ensure it Resolved the FDA's Previously Noted Deficiencies

      Newsfile Press Release.

      Sep 15The Globe and MailUNCY
      UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities Lawsuit - Contact SueWallSt
      Sep 10MorningstarUNCY
      Kaplan Fox Encourages Investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) to Contact the Firm to Learn About Their Legal Rights

      Detailed price information for Unicycive Therapeutics Inc (UNCY-Q) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailUNCY
      Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
      Sep 9MorningstarUNCY
      UNCY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
      Sep 9MorningstarUNCY
      Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
      Sep 8MorningstarUNCY
      UNCY Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Unicycive Therapeutics, Inc.
      Sep 8MorningstarUNCY
      Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

      LOS ALTOS, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 11 a.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website unde

      Sep 1Yahoo FinanceUNCY
      Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Praxis Precision Medicines (PRAX)

      Detailed price information for Tempus AI Cl A (TEM-Q) from The Globe and Mail including charting and trades.

      Aug 21The Globe and MailPRAXUNCY

      This is the newest page. Registered accounts read further back.